Status:
COMPLETED
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
Lead Sponsor:
EMD Serono
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
Up to 18 years
Brief Summary
The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon \[IFN\]-beta-1a) in children and adolescents, using information alrea...
Eligibility Criteria
Inclusion
- Received one or more injections of Rebif® for treatment of a demyelinating event
- Be younger than 18 years of age at time of Rebif® treatment initiation
- Rebif® therapy must have been initiated before June 30, 2009
Exclusion
- No exclusion criteria are applied
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
307 Patients enrolled
Trial Details
Trial ID
NCT01207648
Start Date
July 1 2010
End Date
July 1 2011
Last Update
May 15 2015
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
San Francisco, California, United States
3
Research Site
Boston, Massachusetts, United States
4
Research Site
Buffalo, New York, United States